Adimmune Corporation has made significant strides in global health security by signing the Standard Material Transfer Agreement 2 (SMTA2) under the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework. This agreement, announced today, positions Guoguang Biotech at the forefront of rapid vaccine development in response to influenza pandemics.
By signing the SMTA2, Adimmune ensures it can quickly obtain virus strains from the WHO to expedite the development of vaccines and antiviral drugs during an influenza outbreak. This move underscores the company’s commitment to public health and its readiness to take on corporate responsibilities during health crises.
Despite Taiwan’s non-membership in the WHO, Adimmune’s participation highlights its pivotal role in international health diplomacy and pandemic preparedness. The company has also pledged to donate a significant quantity of vaccines to the WHO once developed, reinforcing global efforts to combat influenza pandemics.
The SMTA2 agreement is part of the WHO’s strategy to engage vaccine and pharmaceutical manufacturers worldwide that have the capability to act swiftly in pandemic situations. Prior to Adimmune, 14 other manufacturers from regions including Europe, the USA, and Asia have joined this initiative. Guoguang Biotech is proud to be the first Taiwanese manufacturer to enter this critical agreement, setting a precedent for future participation from the region.
Furthermore, Adimmune has been an active participant in the global influenza vaccine market since joining the IFPMA Global Influenza Vaccine Supply Task Force in 2012, standing alongside major international firms like Sanofi and GSK. This involvement not only strengthens Taiwan’s domestic capabilities in managing influenza outbreaks but also solidifies its standing as a key player in global epidemic prevention efforts.
